+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Psychedelic Drugs Global Market Report 2024

  • PDF Icon

    Report

  • 200 Pages
  • February 2024
  • Region: Global
  • The Business Research Company
  • ID: 5767359
The psychedelic drugs market size has grown rapidly in recent years. It will grow from $4.88 billion in 2023 to $5.62 billion in 2024 at a compound annual growth rate (CAGR) of 15.1%. The growth observed in the historic period can be attributed to factors such as a shifting regulatory landscape, heightened awareness regarding mental health, and changing public perception.

The psychedelic drugs market size is expected to see rapid growth in the next few years. It will grow to $10.2 billion in 2028 at a compound annual growth rate (CAGR) of 16.1%. The expected growth in the forecast period can be attributed to advancements in drug development, the expansion of therapeutic applications, growing acceptance in the medical community, public policy shifts, and the response to the mental health crisis. Key trends anticipated in the forecast period include a focus on education and public awareness, legal and regulatory developments, diversification of psychedelic compounds, and the adoption of patient-centric treatment approaches.

The surge in cases of mental illnesses is anticipated to drive the expansion of the psychedelic drugs market in the future. Mental illnesses encompass health conditions characterized by alterations in emotion, thinking, or behavior, including distress and post-traumatic stress disorder. Psychedelic drugs have demonstrated effectiveness in treating depression and post-traumatic stress disorder, contributing to the reduction of mental illnesses through regular use. For instance, in November 2022, as reported by the UK-based National Centre for Social Research, the percentage of 17- to 19-year-olds with a suspected mental disorder increased from 17.4% in 2021 to 25.7% in 2022. Consequently, the rising number of mental illness cases is a significant driver behind the growth of the psychedelic drugs market.

Government initiatives and programs related to mental health are poised to further propel the psychedelic drugs market. Government initiatives encompass planned actions, projects, or programs executed by a government to address specific issues, achieve goals, or respond to public needs. These initiatives facilitate research and clinical trials, advancing the understanding of the therapeutic potential and safety profiles of psychedelic substances. Furthermore, regulatory reforms or approvals for medical use, driven by government initiatives, create a more conducive environment for the development and commercialization of psychedelic-based treatments. For example, in February 2022, as reported by Business Insider, the US-based financial and business news website, Chile announced a more than 300% increase in the mental health budget in 2021, and Canada allocated a $1 billion fund for mental health in its 2021 Budget. Hence, government initiatives and mental health programs are significant contributors to the growth of the psychedelic drugs market.

The prevailing trend in the psychedelic drug market is the introduction of depression spray, with major companies taking steps to sustain their positions by offering nasal spray drugs for major depressive disorders. For example, in August 2021, Hikma Pharmaceuticals PLC, a UK-based pharmaceutical company, launched KLOXXADO, an 8 mg nasal spray containing naloxone HCl. This nasal spray is designed for the immediate care of patients, both adults and children, experiencing known or suspected opioid overdoses, as indicated by respiratory depression and/or central nervous system depression.

A notable strategy among major companies in the psychedelic drugs market involves forming partnerships to develop new products and strengthen market positions. Collaborations and partnerships in this sector facilitate the sharing of expertise, resources, and research efforts, expediting the development of innovative treatments and enhancing the understanding of the therapeutic potential of psychedelics. For instance, in March 2022, SciSparc Ltd., an Israel-based biopharmaceutical company, collaborated with Clearmind Medicine Inc., a Canada-based pharmaceutical company. The partnership focuses on exploring the development of innovative compounds in the psychedelic field, aiming to create drug candidates with robust efficacy and safety profiles for treating mental health-related diseases. The collaboration includes joint pre-clinical studies, and both companies anticipate that positive results could deepen their partnership in the pursuit of novel psychedelic-derived therapeutics. This strategic alliance reflects the growing interest and investment in the psychedelic pharmaceutical sector, driven by the potential for groundbreaking treatments and addressing underserved health problems.

In April 2022, Numinus, a Canada-based company specializing in psychedelic medicine with integrated psychotherapy, acquired Novamind for $20.77 million. This acquisition positions Numinus to expand its psychotherapy clinics in the US and advance psychedelic programs. Novamind, a US-based mental health company and psychedelic medicine manufacturer, contributes to Numinus's strategic growth in the evolving landscape of psychedelic treatments.

Major companies operating in the psychedelic drugs market report are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Novartis International AG, AstraZeneca PLC, Roche Holding AG, Takeda Pharmaceutical Company Limited, Mylan N.V., Jazz Pharmaceuticals PLC, Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals PLC, Mydecine Innovations Group Inc., Cybin Inc., Silo Wellness Inc., Emmes Company, Celon Pharma S.A., Klarisana, Mota Ventures Corp., BetterLife Pharma Inc., MindMed Inc., Numinus Wellness Inc., Revive Therapeutics Ltd., Field Trip Health Ltd., Red Light Holland Corp., Avadel Pharmaceuticals PLC, PsyBio Therapeutics Corp., Eleusian Biosciences Corp., Seelos Therapeutics Inc., COMPASS Pathways PLC, NeuroRx Inc.

North America was the largest region in the psychedelic drugs market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the psychedelic drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the psychedelic drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Psychedelic drugs come in different types, including lysergic acid diethylamide (LSD), ketamine, phencyclidine, gamma-hydroxybutyric acid (GHB), and salvia. LSD, colloquially known as acid, is manufactured in crystalline form and diluted for ingestion. These drugs are used for various disease indications such as depression and PTSD, with applications in treatment-resistant depression, opiate addiction, post-traumatic stress disorder, narcolepsy, and panic disorders. Distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies.

The psychedelic drugs market research report is one of a series of new reports that provides psychedelic drugs market statistics, including psychedelic drugs industry global market size, regional shares, competitors with a psychedelic drugs market share, detailed psychedelic drugs market segments, market trends and opportunities, and any further data you may need to thrive in the psychedelic drugs industry. This psychedelic drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The psychedelic drugs market consists of sales of psilocybin, PCP, cannabis, and ecstasy. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.

Table of Contents

1. Executive Summary2. Psychedelic Drugs Market Characteristics3. Psychedelic Drugs Market Trends and Strategies
4. Psychedelic Drugs Market - Macro Economic Scenario
4.1. Impact of High Inflation on the Market
4.2. Ukraine-Russia War Impact on the Market
4.3. COVID-19 Impact on the Market
5. Global Psychedelic Drugs Market Size and Growth
5.1. Global Psychedelic Drugs Market Drivers and Restraints
5.1.1. Drivers of the Market
5.1.2. Restraints of the Market
5.2. Global Psychedelic Drugs Historic Market Size and Growth, 2018-2023, Value ($ Billion)
5.3. Global Psychedelic Drugs Forecast Market Size and Growth, 2023-2028, 2033F, Value ($ Billion)
6. Psychedelic Drugs Market Segmentation
6.1. Global Psychedelic Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Lysergic Acid Diethylamid (LSD)
  • Ketamine
  • Phencyclidine
  • Gamma Hydroxybutyric Acid (GHB)
  • Salvia
6.2. Global Psychedelic Drugs Market, Segmentation by disease Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Depression
  • PTSD
6.3. Global Psychedelic Drugs Market, Segmentation by Origin, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Natural
  • Synthetic
6.4. Global Psychedelic Drugs Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Treatment-Resistant Depression
  • Opiate addiction
  • Post- Traumatic Stress Disorder
  • Narcolepsy
  • Panic Disorders
6.5. Global Psychedelic Drugs Market, Segmentation by Distribution Channle, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
7. Psychedelic Drugs Market Regional and Country Analysis
7.1. Global Psychedelic Drugs Market, Split by Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Psychedelic Drugs Market, Split by Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8. Asia-Pacific Psychedelic Drugs Market
8.1. Asia-Pacific Psychedelic Drugs Market Overview
Region Information, Impact of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Psychedelic Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Psychedelic Drugs Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Psychedelic Drugs Market, Segmentation by Distribution Channle, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
9. China Psychedelic Drugs Market
9.1. China Psychedelic Drugs Market Overview
9.2. China Psychedelic Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Psychedelic Drugs Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Psychedelic Drugs Market, Segmentation by Distribution Channle, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
10. India Psychedelic Drugs Market
10.1. India Psychedelic Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Psychedelic Drugs Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Psychedelic Drugs Market, Segmentation by Distribution Channle, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11. Japan Psychedelic Drugs Market
11.1. Japan Psychedelic Drugs Market Overview
11.2. Japan Psychedelic Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Psychedelic Drugs Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Psychedelic Drugs Market, Segmentation by Distribution Channle, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12. Australia Psychedelic Drugs Market
12.1. Australia Psychedelic Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Psychedelic Drugs Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Psychedelic Drugs Market, Segmentation by Distribution Channle, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13. Indonesia Psychedelic Drugs Market
13.1. Indonesia Psychedelic Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Psychedelic Drugs Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Psychedelic Drugs Market, Segmentation by Distribution Channle, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14. South Korea Psychedelic Drugs Market
14.1. South Korea Psychedelic Drugs Market Overview
14.2. South Korea Psychedelic Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Psychedelic Drugs Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Psychedelic Drugs Market, Segmentation by Distribution Channle, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15. Western Europe Psychedelic Drugs Market
15.1. Western Europe Psychedelic Drugs Market Overview
15.2. Western Europe Psychedelic Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Psychedelic Drugs Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Psychedelic Drugs Market, Segmentation by Distribution Channle, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16. UK Psychedelic Drugs Market
16.1. UK Psychedelic Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Psychedelic Drugs Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Psychedelic Drugs Market, Segmentation by Distribution Channle, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17. Germany Psychedelic Drugs Market
17.1. Germany Psychedelic Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Psychedelic Drugs Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Psychedelic Drugs Market, Segmentation by Distribution Channle, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18. France Psychedelic Drugs Market
18.1. France Psychedelic Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France Psychedelic Drugs Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France Psychedelic Drugs Market, Segmentation by Distribution Channle, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19. Italy Psychedelic Drugs Market
19.1. Italy Psychedelic Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy Psychedelic Drugs Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy Psychedelic Drugs Market, Segmentation by Distribution Channle, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20. Spain Psychedelic Drugs Market
20.1. Spain Psychedelic Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain Psychedelic Drugs Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain Psychedelic Drugs Market, Segmentation by Distribution Channle, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21. Eastern Europe Psychedelic Drugs Market
21.1. Eastern Europe Psychedelic Drugs Market Overview
21.2. Eastern Europe Psychedelic Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Psychedelic Drugs Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Psychedelic Drugs Market, Segmentation by Distribution Channle, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22. Russia Psychedelic Drugs Market
22.1. Russia Psychedelic Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Psychedelic Drugs Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Psychedelic Drugs Market, Segmentation by Distribution Channle, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23. North America Psychedelic Drugs Market
23.1. North America Psychedelic Drugs Market Overview
23.2. North America Psychedelic Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Psychedelic Drugs Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Psychedelic Drugs Market, Segmentation by Distribution Channle, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24. USA Psychedelic Drugs Market
24.1. USA Psychedelic Drugs Market Overview
24.2. USA Psychedelic Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Psychedelic Drugs Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Psychedelic Drugs Market, Segmentation by Distribution Channle, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25. Canada Psychedelic Drugs Market
25.1. Canada Psychedelic Drugs Market Overview
25.2. Canada Psychedelic Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Psychedelic Drugs Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Psychedelic Drugs Market, Segmentation by Distribution Channle, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26. South America Psychedelic Drugs Market
26.1. South America Psychedelic Drugs Market Overview
26.2. South America Psychedelic Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Psychedelic Drugs Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Psychedelic Drugs Market, Segmentation by Distribution Channle, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27. Brazil Psychedelic Drugs Market
27.1. Brazil Psychedelic Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Psychedelic Drugs Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Psychedelic Drugs Market, Segmentation by Distribution Channle, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28. Middle East Psychedelic Drugs Market
28.1. Middle East Psychedelic Drugs Market Overview
28.2. Middle East Psychedelic Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Psychedelic Drugs Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Psychedelic Drugs Market, Segmentation by Distribution Channle, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29. Africa Psychedelic Drugs Market
29.1. Africa Psychedelic Drugs Market Overview
29.2. Africa Psychedelic Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Psychedelic Drugs Market, Segmentation by Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Psychedelic Drugs Market, Segmentation by Distribution Channle, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
30. Psychedelic Drugs Market Competitive Landscape and Company Profiles
30.1. Psychedelic Drugs Market Competitive Landscape
30.2. Psychedelic Drugs Market Company Profiles
30.2.1. Pfizer Inc.
30.2.1.1. Overview
30.2.1.2. Products and Services
30.2.1.3. Strategy
30.2.1.4. Financial Performance
30.2.2. Johnson & Johnson
30.2.2.1. Overview
30.2.2.2. Products and Services
30.2.2.3. Strategy
30.2.2.4. Financial Performance
30.2.3. Merck & Co. Inc.
30.2.3.1. Overview
30.2.3.2. Products and Services
30.2.3.3. Strategy
30.2.3.4. Financial Performance
30.2.4. AbbVie Inc.
30.2.4.1. Overview
30.2.4.2. Products and Services
30.2.4.3. Strategy
30.2.4.4. Financial Performance
30.2.5. Novartis International AG
30.2.5.1. Overview
30.2.5.2. Products and Services
30.2.5.3. Strategy
30.2.5.4. Financial Performance
31. Psychedelic Drugs Market Other Major and Innovative Companies
31.1. AstraZeneca PLC
31.2. Roche Holding AG
31.3. Takeda Pharmaceutical Company Limited
31.4. Mylan N.V.
31.5. Jazz Pharmaceuticals plc
31.6. Dr. Reddy’s Laboratories Ltd
31.7. Hikma Pharmaceuticals PLC
31.8. Mydecine Innovations Group Inc.
31.9. Cybin Inc.
31.10. Silo Wellness Inc.
31.11. Emmes Company
31.12. Celon Pharma S.A.
31.13. Klarisana
31.14. Mota Ventures Corp.
31.15. BetterLife Pharma Inc.
32. Global Psychedelic Drugs Market Competitive Benchmarking33. Global Psychedelic Drugs Market Competitive Dashboard34. Key Mergers and Acquisitions in the Psychedelic Drugs Market
35. Psychedelic Drugs Market Future Outlook and Potential Analysis
35.1 Psychedelic Drugs Market in 2028 - Countries Offering Most New Opportunities
35.2 Psychedelic Drugs Market in 2028 - Segments Offering Most New Opportunities
35.3 Psychedelic Drugs Market in 2028 - Growth Strategies
35.3.1 Market Trend-based Strategies
35.3.2 Competitor Strategies
36. Appendix
36.1. Abbreviations
36.2. Currencies
36.3. Historic and Forecast Inflation Rates
36.4. Research Inquiries
36.5. About the Analyst
36.6. Copyright and Disclaimer

Executive Summary

Psychedelic Drugs Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on psychedelic drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia-Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis.
  • Report will be updated with the latest data and delivered to you with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for psychedelic drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:
  • The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
  • The impact of higher inflation in many countries and the resulting spike in interest rates.
  • The continued but declining impact of COVID-19 on supply chains and consumption patterns.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Report Scope

Markets Covered:
1) By Type: Lysergic Acid Diethylamide (LSD); Ketamine; Phencyclidine; Gamma Hydroxybutyric Acid (GHB); Salvia
2) By Disease Indication: Depression; PTSD
3) By Origin: Natural; Synthetic
4) By Application: Treatment-Resistant Depression; Opiate addiction; Post- Traumatic Stress Disorder; Narcolepsy; Panic Disorders
5) By Distribution Channel: Hospitals Pharmacy; Retail Pharmacy; Online Pharmacy

Key Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Merck & Co. Inc.; AbbVie Inc.; Novartis International AG

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time Series: Five years historic and ten years forecast

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita

Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes

Delivery Format: PDF, Word and Excel Data Dashboard

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Pfizer Inc.
  • Johnson & Johnson
  • Merck & Co. Inc.
  • AbbVie Inc.
  • Novartis International AG
  • AstraZeneca PLC
  • Roche Holding AG
  • Takeda Pharmaceutical Company Limited
  • Mylan N.V.
  • Jazz Pharmaceuticals plc
  • Dr. Reddy’s Laboratories Ltd
  • Hikma Pharmaceuticals PLC
  • Mydecine Innovations Group Inc.
  • Cybin Inc.
  • Silo Wellness Inc.
  • Emmes Company
  • Celon Pharma S.A.
  • Klarisana
  • Mota Ventures Corp.
  • BetterLife Pharma Inc.
  • MindMed Inc.
  • Numinus Wellness Inc.
  • Revive Therapeutics Ltd.
  • Field Trip Health Ltd.
  • Red Light Holland Corp.
  • Avadel Pharmaceuticals plc
  • PsyBio Therapeutics Corp.
  • Eleusian Biosciences Corp.
  • Seelos Therapeutics Inc.
  • COMPASS Pathways plc
  • NeuroRx Inc.

Methodology

Loading
LOADING...